| Literature DB >> 31257999 |
Nelson Lu1, Yunling Xu1, Lilly Q Yue1.
Abstract
Observational (non-randomized) comparative studies have been adopted in the pre-market safety/effectiveness evaluation of medical devices. There has been an increased interest in utilizing this design with the growing available real-world data. However, in such studies, biases that are introduced in every stage and aspect of study need to be addressed. Otherwise, the objectivity of study design and validity of study results will be compromised. In this paper, challenges and opportunities are discussed from the regulatory perspective. Considerations and good statistical practice to mitigate the potential bias are presented.Keywords: Observational comparative studies; propensity score; real-world evidence; study design
Year: 2019 PMID: 31257999 DOI: 10.1080/10543406.2019.1632880
Source DB: PubMed Journal: J Biopharm Stat ISSN: 1054-3406 Impact factor: 1.051